Archive | Of Interest

Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases

In a new clinical validation study, an international team led by investigators at NYU Langone Health has demonstrated that BRAF gene mutations detected in cell-free circulating tumor DNA (ctDNA) can offer a window into treatment response and potential outcomes in individuals with melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Radiotherapy may not improve outcomes in uveal melanoma with extraocular extension

There was no significant difference in survival in eyes that underwent enucleation for uveal melanoma with extraocular extension between postoperative orbital external beam radiotherapy vs. observation, according to a poster presentation.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Neoadjuvant Tavokinogene Telseplasmid Plus Nivolumab Under Evaluation in Advanced Melanoma

The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid (Tavo) in combination with nivolumab (Opdivo) as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial (NCT04526730).1

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Neural network could help clinicians look for ‘ugly duckling’ pre-cancerous skin lesions

A neural network system that analyzes photographs can rank and distinguish suspicious, potentially precancerous skin lesions, which can turn into the deadly skin malignancy melanoma if not caught and removed early.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest